CoChat

The metabolite GLP‐1 (9‐36) is neuroprotective and anti‐inflammatory in cellular models of neurodegeneration

Open access
Li, Yazhou, Glotfelty, Elliot J., Karlsson, Tobias, Fortuno, Lowella V., Harvey, Brandon K., Greig, Nigel H. · 2021 · Journal of Neurochemistry
Cited by 47

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Glucagon‐like peptide‐1 (GLP‐1) is best known for its insulinotropic action following food intake. Its metabolite, GLP‐1 (9‐36), was assumed biologically inactive because of low GLP‐1 receptor (GLP‐1R) affinity and non‐insulinotropic properties; however, recent studies contradict this assumption. Increased use of FDA approved GLP‐1 analogues for treating metabolic disorders and neurodegenerative diseases raises interest in GLP‐1 (9‐36)’s biological role. We use human SH‐SY5Y neuroblastoma cells and a GLP‐1R over‐expressing variety (#9), in both undifferentiated and differentiated states, to evaluate the neurotrophic/neuroprotective effects of GLP‐1 (9‐36) against toxic glutamate exposure and other oxidative stress models (via the MTS, LDH or ROS assays). In addition, we examine GLP‐1 (9‐36)’s signaling pathways, including cyclic‐adenosine monophosphate (cAMP), protein kinase‐A (PKA), and 5’ adenosine monophosphate‐activated protein kinase (AMPK) via the use of ELISA, pharmacological inhibitors, or GLP‐1R antagonist. Human HMC3 and mouse IMG microglial cell lines were used to study the anti‐inflammatory effects of GLP‐1 (9‐36) against lipopolysaccharide (LPS) (via ELISA). Finally, we applied GLP‐1 (9‐36) to primary dissociation cultures challenged with α‐synuclein or amyloid‐β and assessed survival and morphology via immunochemistry. We demonstrate evidence of GLP‐1R, cAMP, PKA, and AMPK‐mediated neurotrophic and neuroprotective effects of GLP‐1 (9‐36). The metabolite significantly reduced IL‐6 and TNF‐α levels in HMC3 and IMG microglial cells, respectively. Lastly, we show mild but significant effects of GLP‐1 (9‐36) in primary neuron cultures challenged with α‐synuclein or amyloid‐β. These studies enhance understanding of GLP‐1 (9‐36)’s effects on the nervous system and its potential as a primary or complementary treatment in pathological contexts. image

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jnc.15521

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 47

Metadata

Authors
Li, Y., Glotfelty, E. J., Karlsson, T., Fortuno, L. V., Harvey, B. K., & Greig, N. H.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2021-10-21
Volume
159
Issue
5
Pages
867-886
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W3203222544
Cited by
47
References
24
FWCI
2.47
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.